Skip to main content
. 2018 Nov 24;10(12):467. doi: 10.3390/cancers10120467

Figure 2.

Figure 2

Performance of PGx profiling (A), G/nab-P sensitivity (B), ΔSMAD4 (C), and a combined analysis (D) to predict treatment response. Six-month PFS was used as a cut-off for predicting sensitivity and response (>6 months) or resistance and lack of response (<6 months).